GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genoptix Inc (DELISTED:GXDX) » Definitions » Price-to-Owner-Earnings

Genoptix (Genoptix) Price-to-Owner-Earnings : (As of May. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Genoptix Price-to-Owner-Earnings?

As of today (2024-05-06), Genoptix's share price is $0.00. Genoptix does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Genoptix's Price-to-Owner-Earnings or its related term are showing as below:


GXDX's Price-to-Owner-Earnings is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 25.42
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-06), Genoptix's share price is $0.00. Genoptix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2010 was $0.00. Therefore, Genoptix's PE Ratio (TTM) for today is N/A.

As of today (2024-05-06), Genoptix's share price is $0.00. Genoptix's EPS without NRI for the trailing twelve months (TTM) ended in was $0.00. Therefore, Genoptix's PE Ratio without NRI for today is N/A.


Genoptix Price-to-Owner-Earnings Historical Data

The historical data trend for Genoptix's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genoptix Price-to-Owner-Earnings Chart

Genoptix Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Genoptix Quarterly Data
Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genoptix's Price-to-Owner-Earnings

For the Diagnostics & Research subindustry, Genoptix's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genoptix's Price-to-Owner-Earnings Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genoptix's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Genoptix's Price-to-Owner-Earnings falls into.



Genoptix Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Genoptix's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.00/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genoptix  (DELISTED:GXDX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Genoptix Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Genoptix's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Genoptix (Genoptix) Business Description

Traded in Other Exchanges
N/A
Address
Website
Genoptix, Inc. incorporated in Delaware in January 1999. It is a specialized laboratory service provider, which is focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists, or hem/oncs. Its group of hematopathologists utilizes diagnostic technologies to provide a differentiated, specialized and integrated assessment of a patient's condition, aiding hem/oncs in making vital decisions concerning the treatment of malignancies of the blood and bone marrow, and other forms of cancer. The company's key service offerings, COMPASS and CHART, are designed to meet the specific needs of community-based hem/oncs. Its COMPASS service offering includes the determination by its hempaths of the appropriate diagnostic tests to be conducted and the performance of these tests. It then evaluate, synthesize and summarize the results into an easy to read comprehensive report, and its hempaths are available to interpret these results jointly with the hem/onc, giving them the benefit of its expertise and analytical experience. The company's CHART service offering combines multiple COMPASS assessments and analyses of disease progression after intervening clinical action, providing the hem/onc with a valuable diagnostic tool to track both a patient's disease and response to the hem/onc's prescribed treatment regimen over time. The Company believes its sales and marketing approach distinguishes it from its competitors. Most of its sales representatives have a four-year Bachelor of Science or Arts degree, primarily in the biological sciences, and a three-to five-year history selling diagnostic services or niche pharmaceuticals directly to hem/oncs. As a specialized diagnostic service provider, it relies extensively on its quality of service to attract and retain community-based hem/oncs and other healthcare professionals as its customers. As a diagnostic service provider, the Company is required to hold certain federal, state and local licenses, certifications and permits to conduct its business.

Genoptix (Genoptix) Headlines

No Headlines